Key Segmentation:
By Product
-
Lutetium-177 Vipivotide Tetraxetan
-
Lutetium-177 Dotatate
-
Radium-223 Dichloride
-
Iobenguane I-131
-
Others
By Indication
-
Prostate Cancer
-
Neuroendocrine Tumors
-
Thyroid Cancer
-
Others
By Target Receptor
-
PSMA
-
SSTR
-
Others
By End User
-
Hospitals & Specialized Cancer Centers
-
Diagnostic & Imaging Centers
-
Academic & Research Institutes
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Indication)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Novartis AG, Eli Lilly and Company, Bayer AG, AstraZeneca plc, and Bristol-Myers Squibb Company, among others.
Key opportunities include expanding indications, next-generation alpha emitters, theranostic integration, emerging-market adoption, and development of novel molecular targets.
The market is driven by rising prostate cancer and neuroendocrine tumor prevalence, growing clinical validation of PSMA- and SSTR-targeted radioligand agents, and continued advancement of isotope production infrastructure.
The Prostate Cancer segment dominated the Radioligand Therapy Market in 2025, accounting for approximately 58.40% market share.
The North America region dominated the Radioligand Therapy Market in 2025, holding an 80.50% market share, driven by mature theranostics infrastructure and favorable reimbursement pathways.
